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Abstract: The mechanism of human labour remains poorly understood, limiting our ability to manage
complications of parturition such as preterm labour and induction of labour. In this study we have
investigated the effect of labour on plasma metabolites immediately following delivery, comparing
cord and maternal plasma taken from women who laboured spontaneously and delivered vaginally
with women who were delivered via elective caesarean section and did not labour. Samples were
analysed using ultra high-performance liquid chromatography-tandem mass spectrometry. Welch’s
two-sample t-test was used to identify any significant differences. Of 826 metabolites measured,
26.9% (222/826) were significantly altered in maternal plasma and 21.1% (174/826) in cord plasma.
Labour involves changes in many maternal organs and poses acute metabolic demands in the uterus
and in the fetus and these are reflected in our results. While a proportion of these differences are likely
to be secondary to the physiological demands of labour itself, these results present a comprehensive
picture of the metabolome in the maternal and fetal circulations at the time of delivery and can be used
to guide future studies. We discuss potential causal pathways for labour including endocannabinoids,
ceramides, sphingolipids and steroids. Further work is necessary to confirm the specific pathways
involved in the spontaneous onset of labour.
Keywords: human parturition; endocannabinoid; steroids; energy metabolism
1. Introduction
Our understanding of the mechanisms of human parturition remains incomplete and consequently
management options for complications of pregnancy such as preterm labour (PTL), and common
interventions such as induction of labour (IOL) [1,2], remain clinically unsatisfactory [3].
A better understanding of human labour at term (defined as 37–42 weeks’ gestation) would allow
development of methods for improved prediction and prevention of PTL, as well as more effective
strategies for IOL [4–6]. The aetiology of PTL is heterogeneous and frequently pathological, however
it may result in stimulation of the same triggers for parturition as spontaneous labour at term [1,7].
The proportion of pregnancies with IOL in England has increased from 20.3% in 2006–2017 to 29.4% in
2016–2017 [4,6,8–10]. IOL can be inefficient, with potentially severe complications for the mother and
neonate, including lengthy hospital stays at high cost to the National Health Service and a negative
impact on the birth experience [3,11,12]. The use of clinical and molecular markers to identify women
at risk of complications of pregnancy remains challenging due to their poor predictive value [13,14].
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There is a need to identify the metabolic changes underlying the physiological onset of spontaneous
human labour and to develop new clinically useful predictive markers and better drug targets.
Metabolomics allows the investigation of a wide range of metabolites across the main biochemical
pathways [15]. The advantage of studying the metabolome or metabolic profile of a system is that it
reveals the current activity rather than a prediction of what may happen, as is the case with genomic
studies [16–18]. The most commonly used metabolomic techniques are mass spectrometry (MS)
and nuclear magnetic resonance (NMR), paired with data processing using advanced computational
programmes [18,19]. NMR can measure a broad range of metabolites however it is less sensitive
than MS. Gas chromatography (GC) or liquid chromatography (LC) coupled to MS provides excellent
separation of molecules within a sample according to their mass-to-charge ratio and analysis at a wide
range of concentrations. As MS is more sensitive, it can be utilised to measure more metabolites, but it
has a longer analysis time than NMR [19]. Metabolomics has been used to investigate pregnancy related
changes in maternal and cord blood, fetal membranes, cervico-vaginal secretions, urine and amniotic
fluid; with the potential of identifying metabolic profiles or biomarkers associated with different
outcomes, such as PTL [20,21], missed miscarriage [22], diagnosis of exposure to chorioamnionitis in
the neonate [23], and the effect of maternal diet on amniotic fluid composition [20,21,24]. However,
to our knowledge there are no previous studies focusing on parturition.
Here we present novel MS data from a pilot study designed to investigate the effect of parturition
on plasma metabolites in the fetal and maternal circulation at the time of delivery and demonstrate
that even with a relatively small sample size significant and robust changes can be identified providing
new insights into the metabolic responses of the maternal-feto-placental unit in spontaneous labour.
2. Materials and Methods
2.1. Participants
Nine women with a vaginal delivery (VD) following active labour of spontaneous onset and ten
women who had an elective caesarean section (CS) for reasons not related to maternal or fetal disease
gave informed, written consent for inclusion before they participated in the study. The study was
conducted in accordance with the Declaration of Helsinki, and ethical approval for the study was
gained from the National Research Ethics Service Committee-South West, Bristol (reference number:
E5431). The inclusion criteria were: women with uncomplicated singleton term pregnancies; age
18–40 years; no significant past medical history. The exclusion criteria were: multiple pregnancies;
age under 18 years or over 41 years of age; taking medications likely to affect metabolomics; diabetes;
pre-eclampsia; other metabolic conditions; raised temperature or signs of fetal distress during labour.
The following demographic information was collected: ethnicity, age, BMI, smoking status, time last
eaten, time of delivery, duration of delivery, drugs given during hospital stay, Apgar scores of the baby,
and cord gases if taken.
2.2. Collection of Samples
Cord blood and maternal (intervillous) blood samples were obtained within 30 minutes of delivery
of the baby and placenta, as described in detail previously [25], following delayed cord clamping
which is routinely carried out at St Michael’s Hospital for both VD and elective CS provided there are
no contraindications. Samples were collected using a sterile 21 Gauge needle and syringe, transferred
into Vacutainer tubes containing EDTA, then centrifuged at 1000× g for ten minutes. 200 µL of the
clear upper plasma layer was transferred into chilled propylene tubes and stored at −80 ◦C.
2.3. Metabolomic Analysis
The samples were transported on dry ice to Metabolon, Inc. (Morrisville, NC, USA) for ultrahigh
performance liquid chromatography-tandem mass spectrometry (UHPLC/MS) [26–28]. All samples
were analysed together in order to reduce risk of batch bias. This included the measurement
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of 826 known metabolites for each sample, grouped into 108 sub-pathways and the following
eight super-pathways: Lipid, Amino Acid, Peptide, Energy, Nucleotide, Cofactors and Vitamins,
and Xenobiotics. Briefly, plasma samples were subjected to methanol extraction then split into aliquots
for analysis by UHPLC/MS in the positive (involving two methods, one optimized for hydrophilic,
and the other hydrophobic compounds), negative or polar ion mode. Metabolites were identified by
automated comparison of ion features to a reference library of chemical standard, followed by visual
inspection for quality control [29]. Multiple water blanks were included on each plate of experimental
samples to identify any compounds resulting from storage or handling. Compounds which were
detected at a level at least triple that found in the water blanks and which were confirmed to be present
relative to a chemical reference standard were included in the final analysis. For quality assurance and
quality control (QC), pooled QC plasma replicates, as well as several internal standards, were assessed
to determine instrument variability, with representative relative standard deviation (RSD) = 3% for
internal standards and 7% for endogenous biochemicals.
2.4. Statistical Analysis
The two experimental groups were labelled VC/EC and VM/EM. VC/EC represents the difference
in the means between VC, the metabolite quantity identified in cord plasma from women who laboured
and delivered vaginally, and EC, the metabolite quantity identified in cord plasma from women
who did not labour and delivered via elective CS. VM/EM represents the difference in the means
between VM, the metabolite quantity identified in intervillous plasma from women who laboured and
delivered vaginally, and EM, the metabolite quantity contained in intervillous plasma from women
who did not labour and delivered via elective CS. Welch’s two-sample t-test was used to identify
metabolites for which the means were significantly different between VC and EC or VM and EM.
Analysis was performed on log-transformed data, considered significant if p ≤ 0.05. A q-value was also
calculated to control for false discovery rate and account for the multiple comparisons which occur in
metabolomic-based studies, where a q-value of <0.10 gives high confidence that a significant difference
is not due to chance.
3. Results
3.1. Demographics
Table 1 presents the characteristics of the labouring and non-labouring groups. All nine women in
the vaginal delivery group had confirmed labours of spontaneous onset. All women were of white
ethnicity and there were no significant differences in age, parity, employment status, Apgar scores
at birth, birthweight or gender of fetus. None of the women had experienced medical complications
during the pregnancy, nor had there been concern for any of the fetuses. The mean BMI at booking was
21.6 in the VD group and 25.6 in the elective CS group (p = 0.02), due to an outlier in the elective CS
group with BMI 38.3. Further analysis was performed and confirmed her inclusion did not affect the
spread of results. The median gestation at delivery was 40 weeks in the VD group and 39 weeks and
2 days in the elective CS group (p = 0.04), an expected difference as planned CSs are routinely booked
between 39 and 40 weeks’ gestation whereas spontaneous deliveries may occur up to three weeks later.
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Table 1. Characteristics of included human participants.
Demographic VDn = 9
Elective CS
n = 10
p Value
(at ≤ 0.05)
Age (years) 32.4 (24–39) a 34.6 (30–40) a NS
BMI at pregnancy booking 21.6 (19.9–23.1) a 25.56 (21.7–38.3) a 0.02
Ethnicity White British: 9 White British: 9White Romanian: 1 NS
Smoking history: NS
Never 8 4
Ex 0 5
Current 1 (4/day) 1 (10/day)
Maternal past medical history
Eczema: 1
ICSI pregnancy (own
sperm/egg): 1
Previous postnatal
depression:1
Well controlled asthma: 1
(MTHFR gene 1): 1
NA
Maternal employment status at
pregnancy booking:
NS
Employed 8 8
Home maker 1 2
Gravida 1.2 (0–2) a 2.4 (0–5) a NS
Parity 0.6 (0–2) a 1.7 (0–7) a NS
Significant pregnancy complications Nil Nil NA
Indication for elective CS NA
Breech: 3
Previous CS: 3
Maternal request: 1
Previous 3rd degree
vaginal tear: 1
Previous traumatic
delivery: 1
Tocophobia: 1
NA
Duration of labour in minutes 312 min (70–650) a NA NA
Gestation at delivery (weeks+days) 40 (38+1–41+6) a 39+2 (38+4–40+3) a 0.04
Apgar scores at 1, 5 and 10 min: NS
8,9,10 1 0
9,10,10 8 10
Management of third stage: NS
Syntometrine or Carbetocin 8 10
Physiological 1 0
Interval between delivery and
freezing of sample (minutes) 38 (36–60)
b 28.5 (24–45) b 0.02
Gender of fetus: NS
Female 5 4
Male 4 6
Apgar scores at 1, 5 and 10 min: NS
8,9,10 1 0
9,10,10 8 10
Birth weight (Kilograms): 3.4 (3.2–3.9) a 3.6 (3.1–4.1) a NS
a Mean (range); b Median (range); VD = Vaginal Delivery; CS = Caesarean Section; BMI = Body Mass Index; NS = not
significant; NA = non-applicable; ICSI = intracytoplasmic sperm injection.
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3.2. Metabolomics
All the results refer to ten women in the elective CS group and nine women in the VD group.
It was not possible to obtain intervillous blood from one placenta, reducing the VM samples to eight.
The numbers of metabolites with significant (p ≤ 0.05) differences between VM and EM, and VC and EC,
in the eight super-pathways are presented in Table 2. Of the 108 metabolite sub-pathways measured,
83 contained metabolites with significant VC/EC and/or VM/EM differences. For the following analysis,
xenobiotic metabolites will be considered separately.
Table 2. Number of metabolites which significantly increased or decreased at the time of delivery
between women who spontaneously laboured and delivered vaginally and women who did not labour
and delivered via elective caesarean section in the maternal (intervillous) plasma (VM/EM) and cord
plasma (VC/EC) for each of the super pathways.
Super Pathway
Number
Metabolites
Measured
Number Significant Changes VM/EM Number Significant Changes VC/EC
↑ ↓ Total (%) ↑ ↓ Total (%)
Lipid 405 139 14 153 (37.8) 73 12 85 (21.0)
Amino Acid 177 9 15 24 (13.6) 15 14 29 (16.4)
Xenobiotics 108 18 3 21 (19.4) 16 5 21 (19.4)
Carbohydrate 29 7 0 7 (24.1) 9 0 9 (31.0)
Cofactors and
Vitamins 31 3 4 7 (22.6) 3 5 8 (25.8)
Energy 11 3 0 3 (27.3) 6 0 6 (54.6)
Nucleotide 38 2 2 4 (10.5) 9 3 12 (31.6)
Peptide 24 0 1 1 (4.2) 3 5 8 (33.3)
Partially characterised 3 2 0 2 0
VM = Maternal (intervillous) plasma from women who laboured and delivered vaginally (n = 8); EM = maternal
plasma from women who did not labour and delivered via caesarean section (n = 10); VC = cord plasma from
women who laboured and delivered vaginally (n = 9); EC= cord plasma from women who did not labour and
delivered via elective caesarean section (n = 10); ↑ = Number of metabolites significantly elevated; ↓ = Number of
metabolites significantly decreased.
3.3. Changes in Cord Plasma Metabolome
Table S1 shows the changes in cord plasma (VC/EC) of specific metabolites within the sub-pathways
ordered according to the magnitude of fold-change. 120 metabolites significantly increased in the cord
plasma of women who laboured, 102 of which also had a significant q value (<0.10), indicating a high
likelihood that the significant change was not due to chance. These comprised 58 lipid metabolites,
14 amino acid metabolites, nine carbohydrate metabolites, eight nucleotide metabolites, six energy
metabolites, three cofactors and vitamins metabolites, two peptide metabolites and two partially
characterised molecules. The metabolite with the largest VC/EC fold-change was heme, which had an
average 14.30-fold increase in the cord plasma (p = 0.024) taken from women who laboured.
Thirty-nine metabolites significantly decreased in the cord plasma of women who laboured
(VC/EC), and 27 of these had a significant q value: eleven amino acids, six lipids, four peptides, three
cofactors and vitamins and three nucleotides.
3.4. Changes in Maternal Plasma Metabolome
Table S2 shows the corresponding changes in maternal plasma metabolites (VM/EM). Overall,
165 metabolites significantly increased in labouring women, all of which had a significant q value.
These included: nine amino acids, seven carbohydrates, three cofactors and vitamins, three energy
metabolites, 139 lipids, two nucleotides, and two partially characterised molecules. The metabolite
with the greatest significant-fold increase in maternal plasma of women who laboured was the
partially characterised molecule glucuronide of C10H18O2 (8), with an average 10.85-fold increase
in VM plasma. The dicarboxylate fatty acids maleate and adipate (C6-DC) increased 10.42-fold and
8.06-fold, respectively.
Thirty-six metabolites were significantly decreased in the maternal plasma of women who laboured
when compared with women who did not labour (VM/EM), with a corresponding significant q value,
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comprising fifteen amino acids, four cofactors and vitamins, fourteen lipids, two nucleotides and one
peptide. Among these were steroid sulphates, including 3-dehydrocholate (p = 0.002), 16α-hydroxy
DHEA 3-sulfate (p = 0.007) and androsteroid monosulfate C19H28O4S (p = 0.017), with 0.13, 0.22 and
0.26 fold-changes, respectively.
3.5. Xenobiotics
The findings within the xenobiotic metabolites were as expected, reflecting the drugs known to
be administered to the women. For example, metronidazole was given to all ten women who were
delivered via elective CS but not to any of the women who delivered vaginally, and this was reflected
in the results (Tables S3 and S4).
3.6. Lipid Super-Pathway
The lipid super-pathway contained the most differences between labouring and non-labouring
women (Figure 1g and Table 2). Most of these changes were significant increases in maternal plasma
(VM/EM). 405 metabolites were identified in this super-pathway: 34.3% (139/405) of the metabolites
significantly increased and 3.5% (14/405) significantly decreased in the maternal plasma of women
who laboured when compared to non-labour; correspondingly, 18.0% (73/405) of the metabolites
significantly increased in the cord plasma of women who laboured, and 3.0% (12/405) significantly
decreased. Of note, 22 sphingolipids (Table S5) significantly increased in maternal plasma of labouring
women with only one corresponding increase found in cord plasma; whereas the sub-pathway with
the most significant changes seen in the cord plasma within the lipid super-pathway were fatty
acid metabolism (acyl carnitine), long chain fatty acids and polyunsaturated fatty acids (Figure 1g).
There were significant increases in the medium and long chain fatty acids in both cord and maternal
plasma and there were selective changes in the maternal and fetal circulation for acyl carnitines, acyl
cholines, and eicosanoids (12-HETE and 23-HHTrE) (Tables S1 and S2).
Of the steroid metabolites, cholesterol was significantly increased in the maternal plasma
of women who laboured (VM/EM) (Table S2) but did not change in the cord plasma (VC/EC).
17α-hydroxypregnenolone 3-sulfate and 21-hydroxypregnenolone monosulfate were significantly
decreased in the maternal plasma of women who laboured (VM/EM), with no corresponding changes
seen in the cord plasma (Table S6). Conversely, progesterone significantly increased in the cord
plasma (VC/EC), with no change seen in maternal plasma (VM/EM). There were significant increases
in 5α-pregnan-3β-ol,20-one sulfate, 5α-pregnan-3β,20β-diol monosulfate, 5α-pregnan-3β,20α-diol
monosulfate, 5α-pregnan-3β,20α-diol monosulfate and pregnanediol-3-glucuronide in maternal
plasma, which were not seen in the cord (Table S7).
Of the endocannabinoid metabolites, three were significantly increased in the cord plasma of
women who laboured when compared with those who did not (VC/EC); and one significantly increased,
and one significantly decreased in the maternal plasma of women who laboured (VM/EM) (Table S8).
Twelve of seventeen ceramide metabolites significantly increased in the maternal plasma (VM/EM),
however there were no such significant differences seen in the cord plasma samples (VC/EC) (Table S9).
Corticosterone significantly increased in maternal plasma (VM/EM) and in cord plasma (VC/EC)
(5.41 and 3.09-fold, respectively) of women who laboured, and the corresponding increases for cortisol
were 5.02-fold and 3.57-fold. There were also significant increases in cortisone and cortisone 21-sulfate
in cord plasma but not in maternal plasma (Tables S1 and S2).
Androstenediol (3β,17β) disulfate and androsteroid monosulfate C19H28O4S significantly
decreased in maternal plasma of women who laboured (VM/EM). 16a-hydroxy DHEA 3-sulfate
significantly decreased in both the cord and maternal plasma. Androsterone glucuronide,
epiandrosterone sulfate, 5α-androstan-3β and 17β-diol disulfate significantly increased in the maternal
plasma, and androsterone sulfate and androstenediol (3α, 17α) monosulfate significantly increased in
both maternal and cord plasma (Tables S1 and S2).
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Figure 1. Comparative histograms showing the number of metabolites with significant changes between
maternal (intervillous) plasma taken from women who laboured and maternal plasma (intervillous)
taken from women who did not labour (VM/EM) compared with cord plasma taken from women who
laboured and cord plasma taken from women who did not labour (VC/EC) for each if the sub-pathways
within the following super-pathways: (a) Amino Acids; (b) Cofactors and Vitamins; (c) Carbohydrates;
(d) Nucleotides; (e) Peptides; (f) Energy; (g) Lipids.
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Of the oestrogenic steroids, estrone 3-sulfate significantly increased in the cord plasma with no
change in the maternal plasma, while estriol 3-sulfate significantly decreased in the maternal plasma
with no change in the cord (Tables S1 and S2).
3.7. Nucleotides
The majority of the significant changes seen within the nucleotide super-pathway were within
VC/EC (Figure 1d), including significant increases in inosine, hypoxanthine, and xanthine, and a
significant decrease in N1-methylinosine. 5-methyluridine (ribothymidine) significantly decreased in
both cord (VC/EC) and maternal plasma (VM/EM), while 5,6-dihydrouracil and xanthosine significantly
increased (Tables S1 and S2).
3.8. Amino Acids
Unlike the other super-pathways, most of the significant changes within the amino-acid
super-pathway were decreases in VC/EC and VM/EM (Figure 1a). Serine, histidine, tryptophan,
N-acetylkynurenine, picolinate, indole-3-carboxylic acid, citrulline and arginine significantly decreased
in both VC/EC and VM/EM.
Carnosine, N-acetyltyrosine and xanthurenate significantly decreased in VC/EC only, while
S-1-pyrroline-5-carboxylate, indolebutyrate, ornithine, homoarginine, threonine, lysine and
trans-4-hydroxyproline decreased in VM/EM only. By contrast, N-acetylaspartate increased 7.14-fold
in VM/EM only, and cysteine-glutathione disulfide increased 5.21-fold in VC/EC (Tables S1 and S2).
3.9. Peptides
Twenty metabolites were measured in this super-pathway (Figure 1e and Table 2). Two of the
four fibrinogen cleavage peptide metabolites measured were significantly increased in cord plasma
of women who laboured compared with non-labour: fibrinopeptide A des-ala increased 12.12-fold
and fibrinopeptide A phosphono-ser increased 11.34-fold. There were no corresponding changes in
maternal plasma.
3.10. Carbohydrate Metabolism
Twenty nine metabolites were measured in this super-pathway (Figure 1c and Table 2), and
of these glucose, maltose, fructose, ribulonate/xylulonate, pyruvate and lactate were significantly
increased in both the cord and maternal plasma taken from women who laboured compared with
non-labour. 3-phosphoglycerate was significantly increased in cord plasma.
3.11. Energy Super-Pathway
Eleven metabolites were measured in this super-pathway (Table 2). Six metabolites of the TCA
cycle were significantly increased in cord plasma of labouring women, but only three increased in
maternal plasma (Tables S1 and S2). There were no significant changes in oxidative phosphorylation.
3.12. Co-Factors and Vitamins
Thirty-one metabolites were measured in this super-pathway (Figure 1b and
Table 2). Of these, 1-methylnicotinamide, N1-methyl-2-pyridone-5-carboxamide and
N1-methyl-4-pyridone-3-carbox-amide from nicotinate and nicotinamide metabolism were
significantly decreased in the cord plasma taken from women who laboured (VC/EC), and adenosine
5’-diphosphoribose (ADP-ribose) significantly increased (Table S1). There were no such changes in the
maternal plasma.
Heme significantly increased 14.3-fold in cord plasma (VC/EC), with no change seen in the maternal
plasma, and two metabolites of vitamin A metabolism and one metabolite of vitamin B6 metabolism
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were significantly increased with labour in maternal plasma (VM/EM), with no corresponding changes
in the cord (Tables S1 and S2).
4. Discussion
To our knowledge, this study is unique in its comparison of the metabolomic profile of cord and
maternal plasma at the time of delivery between women who have laboured and delivered vaginally
and women who have not laboured and delivered via elective caesarean section. The clear-cut
differences in metabolite levels between the two groups confirm the strong impact that active labour
has on both mother and neonate. A proportion of these changes may be due to the stress of labour itself,
but we believe that within these metabolites there are clues as to which pathways trigger spontaneous
parturition in women. In addition, the observed changes in xenobiotics such as metronidazole were
as expected, supporting the robustness of metabolomic methodology in this setting. While it cannot
be ruled out that the intervillous blood samples had some degree of fetal blood contamination, the
very distinct metabolic profiles that we obtained in cord and intervillous plasma confirms the fetal
and maternal circulations were sampled separately [25], thereby confirming the reliability of this
non-invasive method for experimental sampling of maternal blood after delivery.
It could be argued that the stress of labour resembles strenuous exercise, and it would be useful
to look to studies which investigate metabolic changes due to exercise to see if they match any of
the changes observed here. Medium- and long-chain acetylcarnitines increase up to 9-fold following
intense exercise in men [30]. A major source of acetylcarnitine is acetyl Co-A, formed from pyruvate
oxidation, and this increase following exercise is likely due to a switch to increased fatty acid oxidation
in skeletal muscle instead of glycolysis during exercise [31,32]. The significant increases in acylcarnitine
fatty acid metabolism observed in both the cord and maternal plasma of labouring women (VC/EC
and VM/EM) (Tables S1 and S2) could in part be explained by fatty acid oxidation for energy used by
the woman and neonate during labour and delivery. However, while the source of this may be from
working skeletal muscle in the labouring mother, this explanation is less likely in the fetus/neonate
who is not thought to be using their skeletal muscles during labour and delivery. The increased
levels of stress metabolites observed in labour, including cortisol, are likely to be generating fatty acid
mobilisation [33]. The increase in sphingomyelins observed in labouring maternal plasma and the
increase in acylcarnitine fatty acid metabolism in both the cord and maternal plasma of labouring
women could indicate a considerable shift in intermediary metabolism at the time of labour following
the relative decrease of these metabolites in pregnancy [34].
Labour and vaginal delivery would be expected to affect metabolites of fetal and maternal
adrenal origin, particularly glucocorticoids, as part of the physiological stress response [35,36]. In
support of this theory, we found cortisol and its major metabolites cortisone, cortisone 21-sulfate
and corticosterone were significantly increased in the cord plasma of women who spontaneously
laboured and delivered vaginally (VC) when compared with those who did not labour (EC). Similarly,
cortisol and corticosterone were significantly increased in the maternal plasma taken from women who
laboured and delivered vaginally (VM) when compared with those who did not labour (EM) (Tables
S1 and S2). Our data confirm that there is activation of the fetal and maternal adrenal cortex during
labour and vaginal delivery, and while this may be part of the mechanism initiating spontaneous
labour, further studies are needed to investigate this hypothesis.
Within cord plasma (VC/EC), heme was the metabolite with the greatest fold-change (Table S1).
Heme is a complex of iron with protoporphyrin IX, present in haemoglobin and myoglobin. Its levels
in the plasma can increase rapidly following haemolysis or tissue injury [37]. It is possible that the
increased heme present in the cord taken from women who laboured is a marker of the increased
trauma and tissue damage which a neonate experiences during vaginal delivery when compared with
delivery via caesarean section.
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4.1. Endocannabinoids, Ceramides and Sphingolipids
Endocannabinoids have been investigated as biomarkers for reproductive events, with both
predictive and diagnostic uses [38]. Formed from membrane phospholipids, endocannabinoids are
described as non-classical neurotransmitters [38]. Of the two characterised cannabinoid receptors,
CB1 is present in areas of the brain, peripheral nerve terminals and extraneural sites including
the uterus, whereas CB2 is largely limited to cells and organs of the immune system [39].
N-arachidonoylethanolamine (anandamide or AEA) binds to CB1 and CB2 and is broken down by the
enzyme Fatty Acid Amide Hydrolase (FAAH) [39]. Cannabis exogenously acts on the endocannabinoid
system, and its use has been associated with pregnancy complications such as preterm birth, placental
abruption, fetal growth restriction and spontaneous miscarriage [40]. Elevated plasma AEA in early
pregnancy (<8 weeks) and lower peripheral lymphocyte expression of FAAH has been associated
with miscarriage [40,41], and the CB1-knock out mouse has elevated corticotrophin-releasing hormone
(CRH) and spontaneous preterm labour [42]. The uterus can produce its own AEA [39], and myometrial
studies show a concentration-dependent relaxation effect of AEA on human myometrial contraction
in vitro [43]. Of note, FAAH converts AEA to ethanolamine and releases arachidonic acid for
prostaglandin synthesis, providing a potential link between elevated AEA and labour [42]. Ceramide
is a ubiquitous sphingolipid second messenger released rapidly in response to apoptosis and stress [44].
CB1 activation induces sphingomyelin hydrolysis and acute production of ceramide, while CB2
activation leads to de novo sustained ceramide production [39]. The pro-inflammatory cytokine TNFα
is involved in CB1 and CB2 activation and ceramide production [39,44,45], whereby inflammatory
events may stimulate the onset of labour.
In this study, AEA, oleoyl ethanolamide (OEA), and palmitoyl ethanolamide (PEA) were
significantly increased in the cord plasma taken from the women who laboured (VC/EC) (Table S8).
PEA was significantly increased in the corresponding maternal plasma (VM/EM), while N-oleoylserine
significantly decreased in maternal plasma. Interestingly, while in previous studies maternal plasma
AEA has been shown to decline throughout pregnancy until a sharp increase at the time of spontaneous
or induced labour [40,42], we found no difference in the maternal plasma (VM/EM) immediately
following delivery between women who laboured and women who did not; however there was a
significant increase in endocannabinoids, including AEA, in the cord plasma of women who laboured
(VC/EC). It is possible that any increase in AEA is localised to the placenta during labour, and it has
previously been shown that AEA concentrations are significantly higher in the umbilical vein than
the umbilical arteries, which suggests either production by or transportation across the placenta [40].
In addition, we found 71% (12/17) of the measured ceramides increased significantly in the maternal
plasma (VM/EM) (Table S9), while none increased in the cord plasma (VC/EC). Correspondingly, 40%
(22/55) of measured sphingolipids were increased in the maternal plasma (VM/EM) while only 2% (1/55)
significantly changed in the cord plasma (VC/EC). This finding supports previous reports of increased
ceramide levels and expression of serine palmitoyl transferase, the rate-limiting enzyme for ceramide
synthesis de novo, in the placentas of women who laboured compared with those who delivered by
elective CS. This group also reported an increase in interleukin-6, suggesting the involvement of
ceramide signalling and inflammatory mechanisms in labour [46]. Our data support the view that the
endocannabinoid/ceramide/sphingolipid pathway has the potential to stimulate labour [40,42,46].
4.2. Prostaglandins
Prostaglandins are involved in the early preparation for parturition including cervical ripening
(prostaglandin E2) and stimulation of contractility (prostaglandin F2α), as well as rupture of membranes.
Increases in prostaglandins, prostacyclin and their metabolites during advancing labour have been
demonstrated in maternal plasma, amnion and amniotic fluid [47–49]. Prostacyclin and thromboxane
metabolites increase in maternal urine in threatened preterm labour [50], and the prostacyclin metabolite
6-ketoprostaglandin F1α increases in maternal urine both during vaginal delivery and elective CS [51].
In our study, the eicosanoid 12-HETE was significantly increased in the maternal plasma of women
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who laboured and delivered vaginally (VM/EM) (Table S2), however no prostaglandins were detected.
This may be due to the concentrations of prostaglandins in plasma being too low to detect using this
metabolomic platform, or because the samples were collected following placental separation with a
potentially rapid turnover resulting in these eicosanoid metabolites being excreted into the urine prior
to sample collection.
4.3. Progesterone and Pregnenolone
Functional progesterone withdrawal has been linked to the onset of labour [42]. Although there
were no significant differences in progesterone levels in the cord (VC/EC) or maternal (VM/EM) plasma
in our study, there was a significant increase in metabolites of the progestin sub-pathway in the
maternal plasma of labouring women (VM/EM). There is a strong positive correlation of 3β- and
16α-hydroxysteroids with gestational age [52]. This reflects maturation of the fetal adrenal zone and
potential involvement of these metabolites in the preparation for labour.
Parturition has long been associated with changes in progesterone and pregnenolone metabolism
in many species [53,54]. Our findings have uncovered a rich and complex pattern of steroid metabolites
in spontaneous labour and vaginal delivery reflected in both maternal and fetal circulations (Tables
S6 and S7). Of interest is the relative increase in VC/EC of pregnenolone and hydroxypregnenolone
sulfates which are mirrored by changes in the opposite direction in the maternal circulation (Table
S6). Moreover, progesterone and pregnandiol metabolites increased in both the maternal and fetal
circulations (Table S7). These changes indicate increased turnover of C21 compounds, which are the first
steroids derived from cholesterol through the P450scc and 3β-hydroxysteroid dehydrogenase pathway
during labour. We have previously demonstrated changes in cholesterol-transporting lipoproteins in
the maternal circulation in women in spontaneous labour [55], confirming the need for high cholesterol
turnover during parturition. Our results present, for the first time, a comprehensive picture of C21
metabolites in the maternal and fetal circulations in relation to labour and vaginal delivery that can be
used to guide future studies investigating steroid changes at parturition.
4.4. Estrogen
Estrogen synthesis in pregnancy results from the integration of maternal, placental and fetal
tissues [56]. Placental Corticotrophin Releasing Hormone (CRH) stimulates the fetal adrenals to
produce DHEA-sulfate (DHEAS), which is 16-hydroxylated in the fetal liver and converted to estriol
and estrone in the placenta [57,58]. In our study, 16a-hydroxy DHEA 3-sulfate significantly decreased in
both the cord (VC/EC) and maternal plasma (VM/EM), while estriol 3-sulfate significantly decreased in
the maternal plasma (VM/EM) and estrone 3-sulfate significantly increased in the cord plasma (VC/EC)
of women who laboured (Tables S1 and S2). This provides an interesting insight into the effect of
labour on the metabolism of estrogens. It is likely that these changes are related to substrate availability,
including DHEA and its sulfated derivatives, as well as local changes in enzyme activity involving
sulfatases, sulfotransferases, hydroxylases and aromatases, and their redox cofactors including NADH
and NADPH in the uterus, placenta, adrenals, liver and other organs. The regulatory effect of hormones
and growth factors such as CRH [58,59] and epidermal growth factor [60] on each pathway will
be modulated by acute changes in cofactor availability during the process of labour which places
strong energy and redox demands on the uterus. Previously reported increases in the estriol/estradiol
ratio in maternal plasma occur gradually over several weeks before labour onset [59]. Our findings
of a decrease in 16a-hydroxy DHEA 3-sulfate in the cord and maternal plasma and a decrease in
estriol 3-sulfate in the maternal plasma of women who laboured may indicate a sudden decrease in
production of DHEAS by the fetal adrenals at the time of or during spontaneous labour. This adds
further depth to our knowledge of the complex steroid pathways involved in the spontaneous onset of
human labour. In addition, changes in estrogenic metabolites in the maternal and fetal circulations
may not necessarily reflect local tissue changes, such as within the myometrium, which may also have
a functional effect on uterine contractility [61]. While there are many practical advantages in sampling
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the peripheral circulation, and our study provides clear cut overall differences in steroid metabolites
between labouring and non-labouring women, the limitation of metabolomic studies using peripheral
blood is that the dilution effect and the contribution of many organs to steroid metabolism may obscure
local changes in individual tissues. Further work is necessary to understand these mechanisms,
combining peripheral plasma metabolomics with measurements of enzyme activity in specific tissues.
A potential limitation to this study is the relatively low number of participants in each group.
However, clear and significant changes in metabolite levels were identified within this pilot group with
relatively little noise, demonstrating the reliability of this approach. The platform used is very robust
with 26.9% (222/826) of metabolites significantly changing in maternal plasma and 21.1% (174/826)
in cord plasma with labour. The method is unlikely to show false positive results: for example
metronidazole was given at the time of knife-to-skin for all women in the elective CS group, but
none of the women in the VD group received it; reassuringly, all the maternal and cord plasma of the
non-labour group contained metronidazole and none of the labouring group contained it (Tables S3
and S4). Another limitation is the fact that the study is cross sectional, rather than serial, so it is difficult
to know whether the changes observed with labour are part of the mechanism of the initiation of labour
or a consequence of the stress and metabolic demands of several hours of active labour. Nevertheless,
our data show that metabolomic techniques are a powerful approach to identify biochemical changes
associated with labour.
5. Conclusions
In this pilot study we have demonstrated a wide range of metabolic changes at the time of delivery
between women who laboured spontaneously and women who did not labour. The data will be
useful to investigate the biochemical pathways involved in the physiological mechanism of labour in
normal term pregnancy and provide a pattern against which pathological changes in preterm labour
can be compared. Our results demonstrate an interplay between metabolites in the maternal and
fetal circulations which point to the involvement of the endocannabinoid, sphingolipid, ceramide
and steroid systems in the mechanism of active labour. Further studies are now warranted, where
serial maternal samples are taken throughout pregnancy to determine when these changes take place,
especially focusing on the weeks and days immediately prior to spontaneous labour.
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